Publications & Events

Undertaking Phase 1 clinical trials in Australia during a time of uncertainty


In the presence of challenges facing our industry as a result of Coronavirus (COVID-19), Nucleus Network has developed this comprehensive ten-step white paper to help you navigate successful Phase 1 clinical trials in Australia.

Our preparedness as a business to continue to operate and support the clinical trial requirements of our biotech, pharmaceutical and CRO clients is guided by 10 key pillars:

  1. Multi-Site reach in Australia
  2. Size, scale and savings
  3. World-class medical precincts
  4. Social distancing measures
  5. Robust participant pipeline
  6. Rigorous participant screening
  7. Dedicated trial teams
  8. Gold standard infection control
  9. Cross-functional response team
  10. Supply chain surety

These 10 key pillars underpin our processes, behaviors, and values as Australia’s largest Phase 1 clinical trials provider. They also ensure we can continue to support our clients’ clinical trial requirements during this pandemic crisis and prepare them well for the next large-scale challenge.

Nucleus Network is the vital first step in unlocking the next generation of vaccines.

Please enter your contact details below to download the white paper. It is available in English, Mandarin, and Korean - you will be able to choose which version you want to download.